查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
严重肢体缺血市场 - 全球及区域 - 分析与预测（2025 年至 2035 年）
市场调查报告书
商品编码
1759276

严重肢体缺血市场 - 全球及区域 - 分析与预测（2025 年至 2035 年）

Critical Limb Ischemia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

严重肢体缺血是周边动脉疾病(PAD) 的严重晚期阶段，其中流向肢体（通常是脚和腿）的血流量严重减少。

严重肢体缺血是指动脉严重狭窄或阻塞，通常由动脉粥状硬化引起，导致脂肪沉积和斑块在动脉内积聚，从而限制血流。血液循环减少会导致组织缺氧和必需营养物质，进而引发剧烈疼痛、溃疡不癒合、坏疽，在某些情况下甚至需要截肢。

严重肢体缺血与高死亡和残疾风险有关，通常诊断于患有慢性静止痛、伤口不癒合或患肢组织坏死的个体。此病最常见于具有糖尿病、高血压、吸烟和肥胖等风险因素的个体。治疗通常包括药物治疗、微创手术（例如血管成形术和置入术）、外科手术干预，有时还会结合再生疗法来改善血流并保留患肢。早期诊断和介入对于避免包括截肢在内的严重併发症至关重要。

严重肢体缺血市场的主要驱动力之一是糖尿病、高血压、肥胖和吸烟等风险因素的日益普及。这些疾病大大增加了患有周边动脉疾病(PAD) 的几率，如果不及时治疗，可能会发展为严重肢体缺血。随着这些风险因素在全球范围内持续增加，严重肢体缺血的发生率也在上升，增加了对有效治疗的需求。此外，老化也是市场发展的关键驱动力，因为老年人患有严重肢体缺血的风险更高。被诊断患有严重肢体缺血的患者数量不断增加，推动了对先进医疗手段的需求，例如微创手术（切除术、支架植入术、动脉粥样硬化置入术等）和再生疗法，以改善血流并防止肢体缺失。严重肢体缺血负担的持续加重正在推动新治疗方法的开发并扩大市场。

儘管严重肢体缺血市场正在成长，但仍有若干挑战阻碍其发展，特别是血管成形术、置入术和切除术等微创手术，以及干细胞疗法等再生疗法。这些治疗方法通常需要大量资金，因此难以获得，特别是对于中低收入国家和缺乏全面保险的患者而言。此外，严重肢体缺血患者需要长期护理，包括后续观察、药物治疗和持续管理潜在疾病（例如糖尿病和高血压），进一步增加了医疗保健系统的成本负担。这种经济障碍导致治疗延迟或不充分，最终影响患者的预后。经济负担问题仍是阻碍严重肢体缺血治疗广泛应用的关键因素之一。

全球严重肢体缺血市场竞争激烈，多家主要企业推动创新和市场成长。波士顿科学公司、雅培实验室、Rexgenero Ltd.、LimFlow SA、心血管系统公司、拜耳股份公司、Cytori Therapeutics公司、阿斯特捷利康、诺华股份公司、Hemostemix 公司和 Lisata Therapeutics 等公司处于开发和商业化严重肢体缺血治疗方法的前沿。这些公司在推动微创治疗、再生疗法、药物疗法和创新医疗设备方面取得了重大进展，旨在改善患者预后并减少截肢需求。专注于研发、策略伙伴关係以及扩大新兴市场准入，进一步推动了全球严重肢体缺血治疗市场的成长。

市场区隔

细分一：按地区

  • 北美洲
  • 欧洲
  • 亚太地区

全球严重肢体缺血市场正经历重大变革时期，其驱动力源自于新兴趋势，这些趋势正在重塑严重肢体缺血的诊断、治疗和管理方式。诸如血管成形术、置入术和动脉粥状硬化斑块切除术等微创手术的应用日益普及，因其相较于传统手术具有诸多优势，例如恢復时间更快、併发症发生率更低以及患者预后更佳。此外，人们对干细胞疗法和基因疗法等再生医学的日益关注，有望超越单纯的症状管理，透过促进血管生成和改善患肢血流，提供长期解决方案。

促成这一转变的另一个趋势是精准医疗的整合，精准医疗根据每位患者的基因和生物标记数据，量身定制治疗方案，从而实现更有效、更个性化的护理。此外，非侵入性影像和高阶血管造影术等诊断技术的进步，使得更早发现严重不良事件（CLI）成为可能，从而能够更及时地进行干预，防止病情发展到更严重的阶段，例如坏疽和截肢。

全球人口老化以及糖尿病、高血压和肥胖等慢性疾病（这些都是严重肢体缺血的风险因素）的增多，正在推动对创新治疗方案的需求。这促使製药和医疗设备公司加大对新治疗方法、新药物和新器材开发的投资，以满足日益增长的需求。这些趋势不仅改变了严重肢体缺血的临床管理，也为医疗保健领域的成熟和新兴企业参与企业创造了新的市场机会。

本报告研究了全球严重肢体缺血市场，并概述了市场以及区域趋势和公司概况。

目录

执行摘要

第一章 全球严重肢体缺血市场：产业展望

  • 介绍
  • 市场趋势
  • 法律规范
  • 流行病学分析
  • 临床试验分析
  • 市场动态

2. 2023 年至 2035 年全球严重肢体缺血市场（按地区）

  • 北美洲
  • 欧洲
  • 亚太地区

第三章全球严重肢体缺血市场：竞争格局与公司概况

  • 关键策略和发展
    • 合併与收购
    • 协同活动
    • 业务扩展和资金筹措
    • 产品发布和核准
    • 其他活动
  • 公司简介
    • Boston Scientific Corporation Inc.
    • Abbott Laboratories
    • Rexgenero Ltd.
    • LimFlow SA
    • Cardiovascular Systems, Inc.
    • Bayer AG
    • Cytori Therapeutics, Inc.
    • AstraZeneca
    • Novartis AG
    • Hemostemix Inc.
    • Lisata Therapeutics

第四章调查方法

Product Code: BHL3068SA

Global Critical Limb Ischemia Market, Analysis and Forecast: 2025-2035

Critical Limb Ischemia is a severe, advanced stage of peripheral artery disease (PAD), a condition in which there is a significant reduction in blood flow to the extremities, typically the legs and feet. critical limb ischemia occurs when the arteries become severely narrowed or blocked, usually due to atherosclerosis, where fatty deposits or plaque accumulate in the arteries, restricting the blood flow. This reduced circulation deprives the tissues of oxygen and essential nutrients, leading to severe pain, non-healing ulcers, gangrene, and, in some cases, the need for amputation.

critical limb ischemia associated with a high risk of mortality and disability, and it is typically diagnosed in individuals who experience chronic rest pain, wounds that do not heal, or tissue death in the affected limb. The condition is most commonly seen in people with risk factors such as diabetes, hypertension, smoking, and obesity. Treatment usually involves a combination of medical management, minimally invasive procedures (like angioplasty and stenting), surgical interventions, and, in some cases, regenerative therapies to improve blood flow and preserve the affected limb. Early diagnosis and intervention are crucial to avoid severe complications, including amputation.

One of the key drivers of the Critical Limb Ischemia market is the rising prevalence of risk factors such as diabetes, hypertension, obesity, and smoking. These conditions significantly increase the likelihood of developing peripheral artery disease (PAD), which can progress to critical limb ischemia if not treated in time. As these risk factors continue to rise globally, the incidence of critical limb ischemia is also increasing, creating a greater demand for effective treatments. Additionally, the aging population is another important factor driving market growth, as older adults are at a higher risk of developing CLI. The growing number of patients diagnosed with critical limb ischemia is fueling the demand for advanced medical treatments, such as minimally invasive procedures (e.g., angioplasty, stenting, atherectomy) and regenerative therapies, to improve blood flow and prevent limb loss. This increasing burden of critical limb ischemia cases is propelling the development of new therapeutic options, thereby expanding the market.

Despite the growth of the Critical Limb Ischemia market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatment associated with advanced critical limb ischemia therapies, particularly minimally invasive procedures like angioplasty, stenting, and atherectomy, as well as regenerative therapies such as stem cell treatments. These procedures often require significant financial investment, making them less accessible to patients, especially in low- and middle-income countries or for those without comprehensive insurance coverage. Additionally, the long-term care required for critical limb ischemia patients, including follow-up procedures, medications, and ongoing management of underlying conditions (such as diabetes and hypertension), further increases the cost burden on healthcare systems. This financial barrier can lead to delayed or inadequate treatment, which ultimately affects patient outcomes. The challenge of affordability remains one of the key factors limiting the widespread adoption of advanced critical limb ischemia therapies.

The global Critical Limb Ischemia market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Boston Scientific Corporation Inc., Abbott Laboratories, Rexgenero Ltd., LimFlow SA, Cardiovascular Systems, Inc., Bayer AG, Cytori Therapeutics, Inc., AstraZeneca, Novartis AG, Hemostemix Inc., and Lisata Therapeutics are at the forefront of developing and commercializing treatment options for CLI. These companies are making significant strides in advancing minimally invasive procedures, regenerative therapies, pharmaceutical treatments, and innovative medical devices, aimed at improving patient outcomes and reducing the need for amputation. Their focus on research and development, strategic partnerships, and expanding access to new markets is further propelling the growth of the critical limb ischemia treatment market globally.

Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Critical Limb Ischemia market is undergoing significant transformation, fueled by emerging trends that are reshaping the way critical limb ischemia is diagnosed, treated, and managed. Key trends such as the increasing use of minimally invasive procedures, including angioplasty, stenting, and atherectomy, are becoming more prevalent due to their advantages in reducing recovery times, lowering complication rates, and improving patient outcomes compared to traditional surgery. Additionally, the growing focus on regenerative medicine, including stem cell therapies and gene therapies, holds promise for not just managing symptoms but potentially offering long-term solutions by promoting angiogenesis and improving blood flow in the affected limbs.

Another trend contributing to this transformation is the integration of precision medicine, where treatments are tailored to individual patient profiles based on genetic and biomarker data, allowing for more effective and personalized care. Furthermore, advancements in diagnostic technologies, such as non-invasive imaging techniques and advanced angiography, are enabling earlier detection of CLI, allowing for more timely interventions that can prevent the progression to more severe stages, such as gangrene and amputation.

The global aging population and the rise in chronic conditions such as diabetes, hypertension, and obesity, all of which are risk factors for CLI, are driving the demand for innovative treatment options. In response, pharmaceutical companies and medical device manufacturers are increasingly investing in the development of new therapies, drugs, and devices to meet the growing need. These trends are not only transforming the clinical management of critical limb ischemia but also creating new market opportunities for both established players and emerging companies in the healthcare sector.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Critical Limb Ischemia Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Critical Limb Ischemia Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Critical Limb Ischemia Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Critical Limb Ischemia Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Critical Limb Ischemia Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Critical Limb Ischemia Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Boston Scientific Corporation Inc.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Abbott Laboratories
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Rexgenero Ltd.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 LimFlow SA
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Cardiovascular Systems, Inc.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Bayer AG
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
    • 3.2.7 Cytori Therapeutics, Inc.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 AstraZeneca
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Novartis AG
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Hemostemix Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 Lisata Therapeutics
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Critical Limb Ischemia Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Critical Limb Ischemia Market Key Trends, Analysis

List of Tables

  • Table Global Critical Limb Ischemia Market Dynamics, Impact Analysis
  • Table Global Critical Limb Ischemia Market (by Region), $Billion, 2024-2035